Business
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer MIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE)
About this update from Hcw Biologics Inc.
[{"type":"text","content":"NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic Cancer\nMIRAMAR, Fla., Dec. 08, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that under a Cooperative Research and Development Agreement (CRADA), the National Cancer Institute (NCI) and HCW Biologics Inc. (HCW Biologics) will collaborate to perform a Phase 1b/2 clinical study to evaluate the safety and tolerability of HCW Biologics’ proprietary agent, HCW9218, in patients with advanced/metastatic pancreatic cancer. The CRADA is entitled, “A Phase 1b/2 Study of HCW9218, a Bifunctional TGF- β Antagonist/IL-15 Protein Complex, for Advanced Pancreatic Cancer.” The Principal Investigator at NCI is Christine Alewine, M.D., Ph.D. Dr. Alewine is a Lasker Clinical Research Scholar at the National Institutes of Health in the Laboratory of Molecular Biology. Her research focuses on identifying new treatments for pancreatic cancer including pancreatic adenocarcinoma, adenosquamous carcinoma, and acinar cell carcinoma. Dr. Alewine is board certified in internal medicine and medical oncology. About the Center for Cancer Research at the National Cancer Institute:The Center for Cancer Research (CCR), NCI’s specialized internal cancer center, has a robust clinical research program, the largest at the National Institutes of Health. Their physician‐scientists conduct clinical trials that explore unique and understudied questions in cancer research and treatment. CCR collaborates extensively with partners in industry, non‐governmental organizations and academia to conduct clinical trials. As a federally funded entity, a fundamental goal is for CCR to publicize its research activities to the general public. About the Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic CancerSee, “HCW9218 for Advanced Pancreatic Cancer,” at Clinicaltrials.gov Identifier: NCT05304936. About Advanced Pancreatic Cancer:Pancreatic cancer is the third leading cause of cancer death in the United States. The disease accounts for approximately 3% of all cancers. This disease is most frequently diag...